Z-Leu-Leu-Nle-aldehyde

Modify Date: 2024-01-07 19:17:43

Z-Leu-Leu-Nle-aldehyde structure	Common Name	Z-Leu-Leu-Nle-aldehyde
	CAS Number	133407-83-7	Molecular Weight	475.62100
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₆H₄₁N₃O₅	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Z-Leu-Leu-Nle-aldehyde

Z-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a γ-secretase inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia[1][2].

Name	benzyl N-[4-methyl-1-[[4-methyl-1-oxo-1-(1-oxohexan-2-ylamino)pentan-2-yl]amino]-1-oxopentan-2-yl]carbamate
Synonym	More Synonyms

Description	Z-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a γ-secretase inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia[1][2].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> Metabolic Enzyme/Protease >> Proteasome
In Vitro	Z-LLNle-CHO (0-5 µM or 0-3 µM; 72 h) results in a dose-dependent decrease in cell viability/proliferation in six breast cancer cell lines[1]. Z-LLNle-CHO shows proteasome inhibitory activity, which contributes to cytotoxicity to MCF-7 cells[1]. Z-LLNle-CHO blocks Akt-mediated pro-survival pathways and induces caspase- and ROS-dependent cell apoptosis in Nalm6 and 697 cells[2]. Cell Viability Assay[1] Cell Line: MCF-7, BT474, T47D, MDA-MB-231, SKBR3, and MDA-MB-468 cells Concentration: 0-5 µM (for MCF-7); 0-3 µM Incubation Time: 72 h Result: Inhibited MCF-7, BT474, T47D, MDA-MB-231, SKBR3, and MDA-MB-468 cells with ED50 values of 3.25, 2.5, 2.4, 1.8, 1.6, and 1.4 μM, respectively. Apoptosis Analysis[2] Cell Line: Precursor-B ALL cells Concentration: 0-2.5 µM Incubation Time: 18-24 h Result: Induced cell apoptosis.
In Vivo	Z-LLNle-CHO (5 mg/kg; s.c.; single daily for 12 days) inhibits engraftment of B-lymphoblasts in precursor-B ALL xenograft model[2]. Animal Model: Female SCID/NOD mice (6-8-week-old; precursor-B ALL xenograft model)[2]. Dosage: 5 mg/kg Administration: Subcutaneous injection; single daily for 12 days Result: Delayed or prevented engraftment of B-lymphoblasts in 50% of the animals comprising the experimental group.